LIX1L and ovarian cancer: As shown in Fig. 1, LIX1L was strongly expressed in 61.9% of gastric cancer samples (n = 540), 58.1% of pancreatic cancer samples (n = 43), 56% of colon cancer samples (n = 50), 52% of ovarian cancer samples (n = 50), 50% of renal cancer samples (n = 58), 46% of breast cancer samples (n = 50), 45.3% of lung cancer samples (n = 64), 38.3% of hepatocellular cancer samples (n = 47), 29.4% of esophageal cancer samples (n = 51), 24.5% of prostate cancer samples (n = 53) and 24% of thyroid cancer samples (n = 50) (upper panel).